(RTTNews) - Glenmark Pharmaceuticals Ltd. (GLENMARK.NS), Friday announced that it has introduced Latanoprost Ophthalmic Solution, 0.005 percent, a bioequivalent and therapeutically equivalent ...

The US Food and Drug Administration (FDA) has approved a once-daily treatment with netarsudil and latanoprost ophthalmic solution (Rocklatan, Aerie Pharmaceuticals) to decrease elevated intraocular ...

Aerie Pharmaceuticals Announces Acceptance for Review of the Roclanda® (netarsudil and latanoprost ophthalmic solution) 0.02%/0.005% Marketing Authorisation Application in Europe January 02, 2020 ...

DURHAM, N.C.--(BUSINESS WIRE)--Aerie Pharmaceuticals, Inc. (NASDAQ:AERI) (Aerie or the Company), an ophthalmic pharmaceutical company focused on the discovery, development and commercialization of ...

Please provide your email address to receive an email when new articles are posted on . Once-daily dosing of NCX 470 demonstrated noninferiority compared with latanoprost in lowering IOP in patients ...

DURHAM, N.C.--(BUSINESS WIRE)-- Aerie Pharmaceuticals, Inc. (NASDAQ: AERI), an ophthalmic pharmaceutical company focused on the discovery, development and commercialization of first-in-class therapies ...

This article is part of MPR’s coverage of the American Academy of Ophthalmology 2019 Meeting, taking place in San Francisco, CA. Our staff will report on medical research related to eye disorders, ...

Thea Pharma’s work to eliminate preservatives from latanoprost formulations has landed it an FDA nod in open-angle glaucoma and ocular hypertension, clearing the company to launch a differentiated ...

The European Medicines Agency's (EMA's) Committee for Medicinal Products for Human Use (CHMP) has recommended approval of the fixed-dose combination of latanoprost and netarsudil (Roclanda).

Please provide your email address to receive an email when new articles are posted on . Most of us are familiar with the different classes of eye drops. Eye drops are ...

Peapack, New Jersey (May 2, 2002) - Data presented for the first time at the XXIXth International Congress of Ophthalmology in Sydney, Australia, show that long-term (5-year) adjunctive treatment with ...